关键词:

非小细胞肺癌, 脾肺气虚证, 穴位埋线, 健脾清肺汤, 中医证候, 预后

Abstract:

Objective　To explore the influence of acupoint thread embedding combined with Jianpi Qingfei Decoction on traditional Chinese medicine (TCM) syndrome and prognosis of non-small cell lung cancer patients with spleen-lung Qi deficiency syndrome after chemotherapy. Method　A total of 140 non-small cell lung cancer patients with spleen-lung Qi deficiency syndrome after chemotherapy in Shaanxi Provincial Hospital of Traditional Chinese Medicine from May 2022 to January 2024 were selected and were randomly divided into two groups by drawing lots, with 70 cases in each group. There were 45 males and 25 females in the study group, aged (59.26±5.00) years; there were 25 cases of stage Ⅲ and 45 cases of stage Ⅳ; there were 30 cases of squamous cell carcinoma and 40 cases of adenocarcinoma. In the control group, there were 47 males and 23 females, aged (60.14±5.06) years; there were 27 cases of stage Ⅲ and 43 cases of stage Ⅳ; there were 33 cases of squamous cell carcinoma and 37 cases of adenocarcinoma. The control group was treated with Jianpi Qingfei Decoction (400 ml taken warmly twice in the morning and evening), 21 days as 1 cycle, a total of 3 cycles; the study group was treated with acupoint thread embedding on the basis of the control group, once every 10 days, 3 times as a course of treatment, a total of 2 courses of treatment. The TCM syndrome scores, immune cytokines, and tumor markers before and after 63 days of treatment and adverse reactions during treatment were compared between the two groups. t test and χ² test were used for statistical analysis. Results　After treatment, the TCM syndrome scores of both groups were decreased, and those in the study group were lower than those in the control group [cough and phlegm accumulation: (2.11±0.46) points vs. (2.95±0.53) points, fatigue: (2.26±0.16) points vs. (3.31±0.57) points, shortness of breath: (2.11±0.36) points vs. (2.89±0.24) points, loose stools: (1.25±0.43) points vs. (1.60±0.51) points, restlessness: (2.03±0.41) points vs. (3.26±0.53) points], with statistically significant differences (all P<0.05). The levels of squamous cell carcinoma associated antigen (SCC-Ag), gastrin-releasing peptide precursor (ProGRP), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment (CYFRA21-1) in the study group after treatment were lower than those in the control group [(0.94±0.20) μg/L vs. (1.33±0.24) μg/L, (56.24±8.41) ng/L vs. (71.03±10.81) ng/L, (3.21±1.05) μg/L vs. (4.01±1.13) μg/L, (2.03±0.47) μg/L vs. (2.97±0.34) μg/L], with statistically significant differences (all P<0.05). After treatment, the levels of CD4+/CD8+, CD16+CD56+, and interferon (IFN) -γ in the study group were higher than those in the control group, and the level of interleukin-10 was lower than that in the control group, with statistically significant differences (all P<0.05). The incidence of adverse reactions in the study group was 8.57% (6/70), which was lower than that in the control group [22.86% (16/70)], with a statistically significant difference (χ²=5.393, P=0.020). Conclusion　In the treatment of non-small cell lung cancer patients with spleen-lung Qi deficiency syndrome after chemotherapy, acupoint thread embedding combined with Jianpi Qingfei Decoction can alleviate the TCM syndromes, improve the immune function, lower the levels of tumor markers, and has fewer adverse reactions, which can be promoted in clinical practice.

Key words:

Non small cell lung cancer, Spleen-lung Qi deficiency syndrome, Acupoint thread embedding, Jianpi Qingfei Decoction, Traditional Chinese Medicine syndrome, Prognosis